

Supplementary materials

1. Hormone form and dosage

The table below displays the form and dosage of GAHT used by the study participants, at the start of GAHT (e.g. after the baseline measurement) and at the 3-month follow up.

		Transmasculine participants (n = 38)		Transfeminine participants (n = 35)	
		Start of GAHT n = 36	At 3 month follow-up n = 26	Start of GAHT n = 32	At 3 month follow-up n = 24
Measurement					
Cycle regulation use (n, %)	Progestin only – oral	4 (11%)	3 (12%)	-	-
	Progestin only – non-oral methods ¹ .	8 (22%)	3 (12%)	-	-
	Estradiol and progestin – combined oral contraceptives	6 (17%)	0 (0%)	-	-
	None	18 (50%)	6 (23%)	-	-
Testosterone form (n, %)	Transdermal	32 (89%)	19 (73%)	-	-
	Intramuscular – short-acting (esters)	4 (11%)	2 (8%)	-	-
	Intramuscular – long-acting (undecanoate)	0 (0%)	5 (20%)	-	-
Estrogen form (n, %)	Oral	-	-	17 (53%)	14 (46%)
	Transdermal – gel	-	-	3 (9%)	3 (13%)
	Transdermal – spray	-	-	0 (0%)	0 (0%)
	Transdermal – patches	-	-	12 (38%)	7 (29%)
Anti-androgen form (n, %)	GnRH analogues – short-acting	-	-	25 (78%)	13 (54%)
	GnRH analogues – long-acting	-	-	4 (13%)	8 (33%)
	Cyproterone actate	-	-	3 (9%)	3 (13%)

¹. Methods include hormonal intrauterine devices, intramuscular injections, progestin implants

2. Smartsleep mode

The table below displays the outcomes stratified by sleep device setting and the estimated differences between the inactive and the active mode. Analyses show no significant differences between the active and inactive mode of the device.

	TM		Estimated difference active vs. inactive mode ^a .	TF		Estimated difference active vs. inactive mode ^a .
	Means and SD or median and IQR			Means and SD or median and IQR		
Setting	<i>Inactive</i>	<i>Active</i>		<i>Inactive</i>	<i>Active</i>	
Measurement weeks	Baseline: n = 33 3MO: n = 15	Baseline: n = 3 3MO: n = 11	Beta, 95% confidence interval, p-value	Baseline: n = 31 3MO: n = 23	Baseline: n = 1 3MO: n = 1	Beta, 95% confidence interval, p-value
SOL (minutes)	17.8 (7.96 to 33.1)	20.02 (7.96 to 36.7)	-15.5% (-39.1% to 17.7%) P = 0.31	13.98 (7.29 to 27.25)	16.87 (12.22 to 26.85)	3.21% (-10.95 to 19.58) P = 0.68
TST (hours)	7.3 (1.4)	7.6 (1.6)	0.144 (-0.30 to 0.59) P = 0.53	6.49 (1.33)	6.64 (0.67)	0.6594 (-0.251 to 1.559) P = 0.15
WASO (minutes)	20.27 (12.8 to 38.4)	21.0 (15.4 to 28.1)	4.2% (-18.7 to 33.4) p = 0.75	15.79 (9.83 to 37.54)	21.66 (11.18 to 32.1)	-9.998% (-47.56 to 54.47) P = 0.70
NRI	1 (0 to 2)	1 (0 to 2)	6.96% (-10.4% to 27.8%) P = 0.46	1 (0 to 1.5)	1 (0 to 2)	-17.26% (-44.38 to 23.26) P = 0.35
NRA	27 (21 to 40)	26.5 (19 to 43)	-3.1% (-17.6 to 13.9) P = 0.70	27 (41 to 18)	40 (15.5 to 53.5)	- 13.80% (-41.08 to 26.17) P = 0.45
SWS (minutes)	87 (31)	93 (32)	-1.5 (-5.5 to 8.59) P = 0.67	86 (30)	82 (23)	-6.31 (-21.53 to 8.96) P = 0.42
% SWS	20.0% (7.3%)	21.0% (8.0%)	-0.04% (-1.88 to 1.80) P = 0.95	22.6 (8.05)	20.82 (7.02)	-4.3247% (-9.2956 to 0.692) P = 0.091
REM sleep duration (minutes)	118.9 (45.5)	119.1 (38.9)	-9.90 (-23.27 to 3.49) P = 0.149	114.26 (42.9)	106.91 (19.67)	7.938 (-20.63 to 36.28) P = 0.58

REM sleep latency (minutes)	82 (33.5 to 125.5)	68 (28.8 to 101.5)	-1.9% (-29.6 to 39.3) P = 0.95	81.00 (22.5 to 111.5)	89.0 (39.5 to 95.0)	29.74% (-42.66 to 90.51) P = 0.53
^a . Analyzed using a linear mixed model with measurement phase and device setting as fixed predictors and a random intercept per participant, with inactive mode as the reference category.						

3. Participation and non-participation in objective sleep measurements

The table below displays demographic descriptions and questionnaire outcomes of participants who contributed sleep device measurements to the final dataset and participants who did not. It is possible that participants took part in the objective sleep measurements, but that the measurements were of low quality and that they were excluded, which means the participant's measurements are therefore not present in the final dataset.

		Not present in objective sleep measurements	Present in baseline objective sleep measurements only	Present in 3MO objective sleep measurements only	Present in baseline and 3MO
n		26	23	5	45
Age	<i>Median, IQR</i>	22 (20 to 24.5)	24 (21.5 to 26)	28 (19 to 30)	24 (22 to 27)
Group (n, %)	<i>TM</i>	13 (50%)	12 (52%)	2 (40%)	24 (53%)
	<i>TF</i>	13 (50%)	11 (48%)	3 (50%)	21 (47%)
Psychotropic medication use (n, %)	<i>Yes</i>	5 (19%)	2 (9%)	1 (20%)	9 (20%)
	<i>No</i>	21 (81%)	21 (91%)	4 (80%)	36 (80%)
Scores at baseline					
ISI scores (range 0 to 28)	<i>Median</i>	7.5	5.5	6.0	6.0
	<i>IQR</i>	4.75 to 10.25	3.25 to 10.5	4.0 to 6.0	3.0 to 9.0
	<i>missings (n)</i>	2	1	0	0
PSQI scores (range 21)	<i>Median</i>	7	5	4	6
	<i>IQR</i>	4.25 to 9.0	4 to 9	4 to 6	4 to 8
	<i>missings (n)</i>	4	4	0	4
IDS-SR scores (range 0 to 84)	<i>Median</i>	15.5	12	9	12
	<i>IQR</i>	10 to 26	8 to 25.75	8 to 25	8 to 21
	<i>missings (n)</i>	4	1	0	0
PSS scores (range 0 to 40)	<i>Median</i>	13	12	11	10
	<i>IQR</i>	9.5 to 16.25	8.25 to 17	6 to 13	8 to 16
	<i>missings (n)</i>	2	1	0	0